ICICI Prudential Asset Management Co Ltd reduced its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 66.4% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 5,254 shares of the medical instruments supplier’s stock after selling 10,364 shares during the quarter. ICICI Prudential Asset Management Co Ltd’s holdings in West Pharmaceutical Services were worth $1,948,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of WST. Allworth Financial LP increased its holdings in shares of West Pharmaceutical Services by 30.1% during the 3rd quarter. Allworth Financial LP now owns 1,132 shares of the medical instruments supplier’s stock valued at $406,000 after acquiring an additional 262 shares during the last quarter. Eurizon Capital SGR S.p.A. lifted its holdings in West Pharmaceutical Services by 35.8% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 20,980 shares of the medical instruments supplier’s stock worth $7,779,000 after purchasing an additional 5,528 shares during the last quarter. CENTRAL TRUST Co lifted its holdings in West Pharmaceutical Services by 3,125.0% in the 3rd quarter. CENTRAL TRUST Co now owns 258 shares of the medical instruments supplier’s stock worth $96,000 after purchasing an additional 250 shares during the last quarter. Fifth Third Bancorp boosted its position in West Pharmaceutical Services by 1.5% during the third quarter. Fifth Third Bancorp now owns 66,249 shares of the medical instruments supplier’s stock worth $24,563,000 after purchasing an additional 964 shares during the period. Finally, Maryland State Retirement & Pension System boosted its position in West Pharmaceutical Services by 13.6% during the third quarter. Maryland State Retirement & Pension System now owns 4,213 shares of the medical instruments supplier’s stock worth $1,562,000 after purchasing an additional 503 shares during the period. 93.90% of the stock is currently owned by institutional investors.
West Pharmaceutical Services Trading Down 0.0%
Shares of NYSE WST opened at $416.34 on Monday. West Pharmaceutical Services, Inc. has a 1-year low of $223.83 and a 1-year high of $438.27. The company has a current ratio of 2.82, a quick ratio of 2.10 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average of $380.32 and a two-hundred day moving average of $320.84. The company has a market cap of $29.00 billion, a PE ratio of 46.73, a P/E/G ratio of 2.53 and a beta of 1.13.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.20 by $0.46. West Pharmaceutical Services had a return on equity of 21.78% and a net margin of 18.81%. The business had revenue of $874.50 million for the quarter, compared to analyst estimates of $827.12 million. During the same quarter in the prior year, the firm posted $1.96 earnings per share. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, equities analysts expect that West Pharmaceutical Services, Inc. will post 9.45 earnings per share for the current fiscal year.
West Pharmaceutical Services Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 18th. Shareholders of record on Wednesday, November 11th will be issued a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.2%. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.22. The ex-dividend date is Tuesday, November 10th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 11.67%.
Insider Buying and Selling
In other West Pharmaceutical Services news, VP Annette Favorite sold 2,524 shares of West Pharmaceutical Services stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $365.00, for a total transaction of $921,260.00. Following the transaction, the vice president directly owned 21,818 shares in the company, valued at approximately $7,963,570. The trade was a 10.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 15,659 shares of company stock worth $5,443,749. Company insiders own 0.60% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts recently issued reports on WST shares. Citigroup upped their price objective on shares of West Pharmaceutical Services from $412.00 to $494.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Wall Street Zen raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Sunday, November 1st. Evercore reaffirmed an “outperform” rating and set a $425.00 price objective on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Zacks Research lowered West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, TD Cowen raised their price target on shares of West Pharmaceutical Services from $420.00 to $500.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $424.67.
Check Out Our Latest Stock Report on WST
West Pharmaceutical Services Profile
West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.
Read More
- Five stocks we like better than West Pharmaceutical Services
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
